NCT04268706 - Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

March 31, 2037

Conditions

Hodgkin Lymphoma, AdultHodgkin Disease RecurrentHodgkin Disease RefractoryHodgkin Disease, Pediatric

Interventions

DRUG

CD30.CAR-T

Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.

DRUG

Fludarabine

Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days

DRUG

Bendamustine

Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days

Trial Locations (5)

Children's Hospital of Philadelphia, Philadelphia

Sarah Cannon Research Institute, Nashville

University of Chicago Medical Center, Chicago

MD Anderson Cancer Center, Houston

City of Hope Comprehensive Cancer Center, Duarte